APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Rare Disease Drug Industry Research Report 2026

20 December 2025142 pages

Choose your research edition.

Industry ResearchRare Disease Drug Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Rare Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Drug Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Drug Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Rare Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Rare Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Rare Disease Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Rare Disease Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Rare Disease Drug include Alexion Pharmaceuticals, Inc., Amgen, Inc., Atara Biotherapeutics, Bayer AG, Biogen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited and Deciphera, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Rare Disease Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Rare Disease Drug Market by Company

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

Atara Biotherapeutics

Bayer AG

Biogen, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Daiichi Sankyo Company Limited

Deciphera

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Novo Nordisk A/S

ProQR

AstraZeneca

GlaxoSmithKline

Pfizer, Inc.

Eli Lilly and Company

Merck & Co., Inc.

Novartis AG

Johnson & Johnson

Sanofi S.A.

Takeda

Rare Disease Drug Segment by Type

Below 0.1‰

Above 1‰

0.65‰～1‰

Rare Disease Drug Segment by Application

Speciality Pharmacies

Hospital Pharmacies

Retail pharmacies

Others

Rare Disease Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Rare Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Rare Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Rare Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Rare Disease Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Rare Disease Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Rare Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Rare Disease Drug Revenue of Manufacturers (2021-2026) Table 9. Global Rare Disease Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Rare Disease Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Rare Disease Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Rare Disease Drug, Product Type & Application Table 14. Global Rare Disease Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Rare Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Alexion Pharmaceuticals, Inc. Company Information Table 19. Alexion Pharmaceuticals, Inc. Business Overview Table 20. Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio Table 22. Alexion Pharmaceuticals, Inc. Recent Developments Table 23. Amgen, Inc. Company Information Table 24. Amgen, Inc. Business Overview Table 25. Amgen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amgen, Inc. Rare Disease Drug Product Portfolio Table 27. Amgen, Inc. Recent Developments Table 28. Atara Biotherapeutics Company Information Table 29. Atara Biotherapeutics Business Overview Table 30. Atara Biotherapeutics Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Atara Biotherapeutics Rare Disease Drug Product Portfolio Table 32. Atara Biotherapeutics Recent Developments Table 33. Bayer AG Company Information Table 34. Bayer AG Business Overview Table 35. Bayer AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bayer AG Rare Disease Drug Product Portfolio Table 37. Bayer AG Recent Developments Table 38. Biogen, Inc. Company Information Table 39. Biogen, Inc. Business Overview Table 40. Biogen, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Biogen, Inc. Rare Disease Drug Product Portfolio Table 42. Biogen, Inc. Recent Developments Table 43. Bristol-Myers Squibb Company Company Information Table 44. Bristol-Myers Squibb Company Business Overview Table 45. Bristol-Myers Squibb Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio Table 47. Bristol-Myers Squibb Company Recent Developments Table 48. Celgene Corporation Company Information Table 49. Celgene Corporation Business Overview Table 50. Celgene Corporation Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Celgene Corporation Rare Disease Drug Product Portfolio Table 52. Celgene Corporation Recent Developments Table 53. Daiichi Sankyo Company Limited Company Information Table 54. Daiichi Sankyo Company Limited Business Overview Table 55. Daiichi Sankyo Company Limited Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio Table 57. Daiichi Sankyo Company Limited Recent Developments Table 58. Deciphera Company Information Table 59. Deciphera Business Overview Table 60. Deciphera Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Deciphera Rare Disease Drug Product Portfolio Table 62. Deciphera Recent Developments Table 63. Eisai Co., Ltd. Company Information Table 64. Eisai Co., Ltd. Business Overview Table 65. Eisai Co., Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Eisai Co., Ltd. Rare Disease Drug Product Portfolio Table 67. Eisai Co., Ltd. Recent Developments Table 68. F. Hoffmann-La Roche Ltd. Company Information Table 69. F. Hoffmann-La Roche Ltd. Business Overview Table 70. F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio Table 72. F. Hoffmann-La Roche Ltd. Recent Developments Table 73. Novo Nordisk A/S Company Information Table 74. Novo Nordisk A/S Business Overview Table 75. Novo Nordisk A/S Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Novo Nordisk A/S Rare Disease Drug Product Portfolio Table 77. Novo Nordisk A/S Recent Developments Table 78. ProQR Company Information Table 79. ProQR Business Overview Table 80. ProQR Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. ProQR Rare Disease Drug Product Portfolio Table 82. ProQR Recent Developments Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AstraZeneca Rare Disease Drug Product Portfolio Table 87. AstraZeneca Recent Developments Table 88. GlaxoSmithKline Company Information Table 89. GlaxoSmithKline Business Overview Table 90. GlaxoSmithKline Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline Rare Disease Drug Product Portfolio Table 92. GlaxoSmithKline Recent Developments Table 93. Pfizer, Inc. Company Information Table 94. Pfizer, Inc. Business Overview Table 95. Pfizer, Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Pfizer, Inc. Rare Disease Drug Product Portfolio Table 97. Pfizer, Inc. Recent Developments Table 98. Eli Lilly and Company Company Information Table 99. Eli Lilly and Company Business Overview Table 100. Eli Lilly and Company Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Eli Lilly and Company Rare Disease Drug Product Portfolio Table 102. Eli Lilly and Company Recent Developments Table 103. Merck & Co., Inc. Company Information Table 104. Merck & Co., Inc. Business Overview Table 105. Merck & Co., Inc. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Merck & Co., Inc. Rare Disease Drug Product Portfolio Table 107. Merck & Co., Inc. Recent Developments Table 108. Novartis AG Company Information Table 109. Novartis AG Business Overview Table 110. Novartis AG Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Novartis AG Rare Disease Drug Product Portfolio Table 112. Novartis AG Recent Developments Table 113. Johnson & Johnson Company Information Table 114. Johnson & Johnson Business Overview Table 115. Johnson & Johnson Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Johnson & Johnson Rare Disease Drug Product Portfolio Table 117. Johnson & Johnson Recent Developments Table 118. Sanofi S.A. Company Information Table 119. Sanofi S.A. Business Overview Table 120. Sanofi S.A. Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sanofi S.A. Rare Disease Drug Product Portfolio Table 122. Sanofi S.A. Recent Developments Table 123. Takeda Company Information Table 124. Takeda Business Overview Table 125. Takeda Rare Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Takeda Rare Disease Drug Product Portfolio Table 127. Takeda Recent Developments Table 128. Global Rare Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 129. Global Rare Disease Drug Sales by Region (2021-2026) & (K Units) Table 130. Global Rare Disease Drug Sales Market Share by Region (2021-2026) Table 131. Global Rare Disease Drug Sales by Region (2027-2032) & (K Units) Table 132. Global Rare Disease Drug Sales Market Share by Region (2027-2032) Table 133. Global Rare Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 134. Global Rare Disease Drug Revenue Market Share by Region (2021-2026) Table 135. Global Rare Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 136. Global Rare Disease Drug Revenue Market Share by Region (2027-2032) Table 137. North America Rare Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. North America Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 139. North America Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 140. North America Rare Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Rare Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Europe Rare Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Europe Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 144. Europe Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 145. Europe Rare Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Europe Rare Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. Asia Pacific Rare Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Asia Pacific Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 149. Asia Pacific Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 150. Asia Pacific Rare Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 151. Asia Pacific Rare Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 152. South America Rare Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. South America Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 154. South America Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 155. South America Rare Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 156. South America Rare Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa Rare Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Middle East and Africa Rare Disease Drug Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa Rare Disease Drug Sales by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Rare Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa Rare Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 162. Global Rare Disease Drug Sales by Type (2021-2026) & (K Units) Table 163. Global Rare Disease Drug Sales by Type (2027-2032) & (K Units) Table 164. Global Rare Disease Drug Sales Market Share by Type (2021-2026) Table 165. Global Rare Disease Drug Sales Market Share by Type (2027-2032) Table 166. Global Rare Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 167. Global Rare Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 168. Global Rare Disease Drug Revenue Market Share by Type (2021-2026) Table 169. Global Rare Disease Drug Revenue Market Share by Type (2027-2032) Table 170. Global Rare Disease Drug Price by Type (2021-2026) & (US$/Unit) Table 171. Global Rare Disease Drug Price by Type (2027-2032) & (US$/Unit) Table 172. Global Rare Disease Drug Sales by Application (2021-2026) & (K Units) Table 173. Global Rare Disease Drug Sales by Application (2027-2032) & (K Units) Table 174. Global Rare Disease Drug Sales Market Share by Application (2021-2026) Table 175. Global Rare Disease Drug Sales Market Share by Application (2027-2032) Table 176. Global Rare Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 177. Global Rare Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 178. Global Rare Disease Drug Revenue Market Share by Application (2021-2026) Table 179. Global Rare Disease Drug Revenue Market Share by Application (2027-2032) Table 180. Global Rare Disease Drug Price by Application (2021-2026) & (US$/Unit) Table 181. Global Rare Disease Drug Price by Application (2027-2032) & (US$/Unit) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. Rare Disease Drug Distributors List Table 185. Rare Disease Drug Customers List Table 186. Rare Disease Drug Industry Trends Table 187. Rare Disease Drug Industry Drivers Table 188. Rare Disease Drug Industry Restraints Table 189. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Rare Disease Drug Product Image Figure 5. Global Rare Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Rare Disease Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Rare Disease Drug Sales (2021-2032) & (K Units) Figure 8. Global Rare Disease Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Below 0.1‰ Product Image Figure 10. Above 1‰ Product Image Figure 11. 0.65‰～1‰ Product Image Figure 12. Speciality Pharmacies Product Image Figure 13. Hospital Pharmacies Product Image Figure 14. Retail pharmacies Product Image Figure 15. Others Product Image Figure 16. Global Rare Disease Drug Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Rare Disease Drug Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Rare Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Rare Disease Drug Sales by Region in 2025 Figure 22. Global Rare Disease Drug Revenue by Region in 2025 Figure 23. North America Rare Disease Drug Market Size by Country in 2025 Figure 24. North America Rare Disease Drug Sales Market Share by Country (2021-2032) Figure 25. North America Rare Disease Drug Revenue Market Share by Country (2021-2032) Figure 26. United States Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Rare Disease Drug Market Size by Country in 2025 Figure 29. Europe Rare Disease Drug Sales Market Share by Country (2021-2032) Figure 30. Europe Rare Disease Drug Revenue Market Share by Country (2021-2032) Figure 31. Germany Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Rare Disease Drug Market Size by Country in 2025 Figure 37. Asia Pacific Rare Disease Drug Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Rare Disease Drug Revenue Market Share by Country (2021-2032) Figure 39. China Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Rare Disease Drug Market Size by Country in 2025 Figure 48. South America Rare Disease Drug Sales Market Share by Country (2021-2032) Figure 49. South America Rare Disease Drug Revenue Market Share by Country (2021-2032) Figure 50. Mexico Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Rare Disease Drug Market Size by Country in 2025 Figure 54. Middle East and Africa Rare Disease Drug Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Rare Disease Drug Revenue Market Share by Country (2021-2032) Figure 56. Turkey Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Rare Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Rare Disease Drug Sales Market Share by Type (2021-2032) Figure 60. Global Rare Disease Drug Revenue Market Share by Type (2021-2032) Figure 61. Global Rare Disease Drug Price (US$/Unit) by Type (2021-2032) Figure 62. Global Rare Disease Drug Sales Market Share by Application (2021-2032) Figure 63. Global Rare Disease Drug Revenue Market Share by Application (2021-2032) Figure 64. Global Rare Disease Drug Price (US$/Unit) by Application (2021-2032) Figure 65. Rare Disease Drug Value Chain Figure 66. Rare Disease Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Rare Disease Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Below 0.1‰
  • Above 1‰
  • 0.65‰～1‰
Applications
  • Speciality Pharmacies
  • Hospital Pharmacies
  • Retail pharmacies
  • Others
Companies covered
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • Atara Biotherapeutics
  • Bayer AG
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • Deciphera
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • ProQR
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Takeda

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Rare Disease Drug Market Size (2021-2032)
  4. 2.2.2 Global Rare Disease Drug Sales (2021-2032)
  5. 2.2.3 Global Rare Disease Drug Market Average Price (2021-2032)
  6. 2.3 Rare Disease Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Below 0.1‰
  9. 2.3.3 Above 1‰
  10. 2.3.4 0.65‰～1‰
  11. 2.4 Rare Disease Drug by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Speciality Pharmacies
  14. 2.4.3 Hospital Pharmacies
  15. 2.4.4 Retail pharmacies
  16. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Rare Disease Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Rare Disease Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Rare Disease Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Rare Disease Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Rare Disease Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Rare Disease Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Rare Disease Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Rare Disease Drug, Established Date
  9. 3.9 Global Rare Disease Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Alexion Pharmaceuticals, Inc.
  2. 4.1.1 Alexion Pharmaceuticals, Inc. Company Information
  3. 4.1.2 Alexion Pharmaceuticals, Inc. Business Overview
  4. 4.1.3 Alexion Pharmaceuticals, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Alexion Pharmaceuticals, Inc. Rare Disease Drug Product Portfolio
  6. 4.1.5 Alexion Pharmaceuticals, Inc. Recent Developments
  7. 4.2 Amgen, Inc.
  8. 4.2.1 Amgen, Inc. Company Information
  9. 4.2.2 Amgen, Inc. Business Overview
  10. 4.2.3 Amgen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amgen, Inc. Rare Disease Drug Product Portfolio
  12. 4.2.5 Amgen, Inc. Recent Developments
  13. 4.3 Atara Biotherapeutics
  14. 4.3.1 Atara Biotherapeutics Company Information
  15. 4.3.2 Atara Biotherapeutics Business Overview
  16. 4.3.3 Atara Biotherapeutics Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Atara Biotherapeutics Rare Disease Drug Product Portfolio
  18. 4.3.5 Atara Biotherapeutics Recent Developments
  19. 4.4 Bayer AG
  20. 4.4.1 Bayer AG Company Information
  21. 4.4.2 Bayer AG Business Overview
  22. 4.4.3 Bayer AG Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bayer AG Rare Disease Drug Product Portfolio
  24. 4.4.5 Bayer AG Recent Developments
  25. 4.5 Biogen, Inc.
  26. 4.5.1 Biogen, Inc. Company Information
  27. 4.5.2 Biogen, Inc. Business Overview
  28. 4.5.3 Biogen, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Biogen, Inc. Rare Disease Drug Product Portfolio
  30. 4.5.5 Biogen, Inc. Recent Developments
  31. 4.6 Bristol-Myers Squibb Company
  32. 4.6.1 Bristol-Myers Squibb Company Company Information
  33. 4.6.2 Bristol-Myers Squibb Company Business Overview
  34. 4.6.3 Bristol-Myers Squibb Company Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Bristol-Myers Squibb Company Rare Disease Drug Product Portfolio
  36. 4.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 4.7 Celgene Corporation
  38. 4.7.1 Celgene Corporation Company Information
  39. 4.7.2 Celgene Corporation Business Overview
  40. 4.7.3 Celgene Corporation Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Celgene Corporation Rare Disease Drug Product Portfolio
  42. 4.7.5 Celgene Corporation Recent Developments
  43. 4.8 Daiichi Sankyo Company Limited
  44. 4.8.1 Daiichi Sankyo Company Limited Company Information
  45. 4.8.2 Daiichi Sankyo Company Limited Business Overview
  46. 4.8.3 Daiichi Sankyo Company Limited Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Daiichi Sankyo Company Limited Rare Disease Drug Product Portfolio
  48. 4.8.5 Daiichi Sankyo Company Limited Recent Developments
  49. 4.9 Deciphera
  50. 4.9.1 Deciphera Company Information
  51. 4.9.2 Deciphera Business Overview
  52. 4.9.3 Deciphera Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Deciphera Rare Disease Drug Product Portfolio
  54. 4.9.5 Deciphera Recent Developments
  55. 4.10 Eisai Co., Ltd.
  56. 4.10.1 Eisai Co., Ltd. Company Information
  57. 4.10.2 Eisai Co., Ltd. Business Overview
  58. 4.10.3 Eisai Co., Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Eisai Co., Ltd. Rare Disease Drug Product Portfolio
  60. 4.10.5 Eisai Co., Ltd. Recent Developments
  61. 4.11 F. Hoffmann-La Roche Ltd.
  62. 4.11.1 F. Hoffmann-La Roche Ltd. Company Information
  63. 4.11.2 F. Hoffmann-La Roche Ltd. Business Overview
  64. 4.11.3 F. Hoffmann-La Roche Ltd. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 F. Hoffmann-La Roche Ltd. Rare Disease Drug Product Portfolio
  66. 4.11.5 F. Hoffmann-La Roche Ltd. Recent Developments
  67. 4.12 Novo Nordisk A/S
  68. 4.12.1 Novo Nordisk A/S Company Information
  69. 4.12.2 Novo Nordisk A/S Business Overview
  70. 4.12.3 Novo Nordisk A/S Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Novo Nordisk A/S Rare Disease Drug Product Portfolio
  72. 4.12.5 Novo Nordisk A/S Recent Developments
  73. 4.13 ProQR
  74. 4.13.1 ProQR Company Information
  75. 4.13.2 ProQR Business Overview
  76. 4.13.3 ProQR Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 ProQR Rare Disease Drug Product Portfolio
  78. 4.13.5 ProQR Recent Developments
  79. 4.14 AstraZeneca
  80. 4.14.1 AstraZeneca Company Information
  81. 4.14.2 AstraZeneca Business Overview
  82. 4.14.3 AstraZeneca Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AstraZeneca Rare Disease Drug Product Portfolio
  84. 4.14.5 AstraZeneca Recent Developments
  85. 4.15 GlaxoSmithKline
  86. 4.15.1 GlaxoSmithKline Company Information
  87. 4.15.2 GlaxoSmithKline Business Overview
  88. 4.15.3 GlaxoSmithKline Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 GlaxoSmithKline Rare Disease Drug Product Portfolio
  90. 4.15.5 GlaxoSmithKline Recent Developments
  91. 4.16 Pfizer, Inc.
  92. 4.16.1 Pfizer, Inc. Company Information
  93. 4.16.2 Pfizer, Inc. Business Overview
  94. 4.16.3 Pfizer, Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Pfizer, Inc. Rare Disease Drug Product Portfolio
  96. 4.16.5 Pfizer, Inc. Recent Developments
  97. 4.17 Eli Lilly and Company
  98. 4.17.1 Eli Lilly and Company Company Information
  99. 4.17.2 Eli Lilly and Company Business Overview
  100. 4.17.3 Eli Lilly and Company Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Eli Lilly and Company Rare Disease Drug Product Portfolio
  102. 4.17.5 Eli Lilly and Company Recent Developments
  103. 4.18 Merck & Co., Inc.
  104. 4.18.1 Merck & Co., Inc. Company Information
  105. 4.18.2 Merck & Co., Inc. Business Overview
  106. 4.18.3 Merck & Co., Inc. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Merck & Co., Inc. Rare Disease Drug Product Portfolio
  108. 4.18.5 Merck & Co., Inc. Recent Developments
  109. 4.19 Novartis AG
  110. 4.19.1 Novartis AG Company Information
  111. 4.19.2 Novartis AG Business Overview
  112. 4.19.3 Novartis AG Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Novartis AG Rare Disease Drug Product Portfolio
  114. 4.19.5 Novartis AG Recent Developments
  115. 4.20 Johnson & Johnson
  116. 4.20.1 Johnson & Johnson Company Information
  117. 4.20.2 Johnson & Johnson Business Overview
  118. 4.20.3 Johnson & Johnson Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Johnson & Johnson Rare Disease Drug Product Portfolio
  120. 4.20.5 Johnson & Johnson Recent Developments
  121. 4.21 Sanofi S.A.
  122. 4.21.1 Sanofi S.A. Company Information
  123. 4.21.2 Sanofi S.A. Business Overview
  124. 4.21.3 Sanofi S.A. Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Sanofi S.A. Rare Disease Drug Product Portfolio
  126. 4.21.5 Sanofi S.A. Recent Developments
  127. 4.22 Takeda
  128. 4.22.1 Takeda Company Information
  129. 4.22.2 Takeda Business Overview
  130. 4.22.3 Takeda Rare Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Takeda Rare Disease Drug Product Portfolio
  132. 4.22.5 Takeda Recent Developments
5 Global Rare Disease Drug Market Scenario by Region
  1. 5.1 Global Rare Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Rare Disease Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Rare Disease Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Rare Disease Drug Sales by Region: 2027-2032
  5. 5.3 Global Rare Disease Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Rare Disease Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Rare Disease Drug Revenue by Region: 2027-2032
  8. 5.4 North America Rare Disease Drug Market Facts & Figures by Country
  9. 5.4.1 North America Rare Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Rare Disease Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Rare Disease Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Rare Disease Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Rare Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Rare Disease Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Rare Disease Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Rare Disease Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Rare Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Rare Disease Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Rare Disease Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Rare Disease Drug Market Facts & Figures by Country
  35. 5.7.1 South America Rare Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Rare Disease Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Rare Disease Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Rare Disease Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Rare Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Rare Disease Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Rare Disease Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Rare Disease Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Rare Disease Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Rare Disease Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Rare Disease Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Rare Disease Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Rare Disease Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Rare Disease Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Rare Disease Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Rare Disease Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Rare Disease Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Rare Disease Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Rare Disease Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Rare Disease Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Rare Disease Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Rare Disease Drug Value Chain Analysis
  2. 8.1.1 Rare Disease Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Rare Disease Drug Production Mode & Process
  5. 8.2 Rare Disease Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Rare Disease Drug Distributors
  8. 8.2.3 Rare Disease Drug Customers
9 Global Rare Disease Drug Analyzing Market Dynamics
  1. 9.1 Rare Disease Drug Industry Trends
  2. 9.2 Rare Disease Drug Industry Drivers
  3. 9.3 Rare Disease Drug Industry Opportunities and Challenges
  4. 9.4 Rare Disease Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst